OKYO

1.1054.74%
GS

Gary S. Jacob

Chief Development Officer & Director

Dr. Gary S. Jacob, PhD, serves as Inside Director, Chief Executive Officer and Chief Scientific Officer an at Virpax Pharmaceuticals, Inc. since April 2020. He had been an Independent Director of Cardiff Oncology, Inc. since February 2009 until June 10, 2021. He served as Chief Executive Officer of OKYO Pharma Limited since January 7, 2021 until January 5, 2025 and serves as Chief Development Officer from January 5, 2025 and serves as its Director since January 7, 2021. He had been Independent Chairman of Hepion Pharmaceuticals, Inc. since March 19, 2014, until February 20, 2024 and served as its Director since May 15, 2013, until February 20, 2024 and served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. He has been an Independent Director of Actavia Life Sciences, Inc. (formerly known as Rasna Therapeutics, Inc.) since December 23, 2020. From 1997 to 1998 was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. From of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England. Dr. Jacob has extensive experience in the pharmaceutical and biotechnology industries across multiple disciplines, including research and development, operations, business development, capital financing activities and senior management expertise. He is the Co-Founder of Synergy Pharmaceuticals and has developed broad and influential contacts throughout the biopharmaceutical, financial, banking and Investor communities. He served as Chairman of the Board from September 2013 to November 2018, President and Chief Executive Officer of Synergy Pharmaceuticals, Inc. where he held various positions from July 2008 until November 2018 and is the co-inventor of the FDA-approved drug Trulance® which is marketed in the U.S. by Bausch Health Companies, Inc. to treat functional GI disorders. From November 2018 to March 2020, Dr. Jacob served as the Chief Executive Officer and Managing Director of Immuron, Ltd. He served as Chief Executive Officer and Director of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Prior to his involvement with Callisto and Synergy, Dr. Jacob spent at Monsanto/G.D. Searle, where he was Director of Glycobiology and a Monsanto Science Fellow, specializing in the field of Glycobiology and drug discovery from 1990 to 1997. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Incorporated. Dr. Jacob holds over 30 patents. Dr. Jacob earned a B.S. cum laude in Chemistry from the University of Missouri – St. Louis and holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison.

Positions